Eloxx Pharmaceuticals, Inc. Common Stock(ELOX)

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership.

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

Snapshot
Fair Value

A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.

  • DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
  • Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
  • DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 0.5% and dividend payments are stable.
  • P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
  • Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
  • Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
  • Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
  • Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
10-yr Treasury (rf)4.53%
Beta vs SPY1.00
Cost of Equity (CAPM)9.53%
WACC9.55%
Effective Tax Rate21.0%
Rev. Growth (YoY, DCF input)+3.0%
DCF Horizon5 years explicit + fade
Forward Tilt (NTM/TTM)×1.03 (applied to P/E, EV/EBITDA, P/S)
Return on Equity (TTM)62.7%
Book / Price-454.5%
Quality Score1/6 — cyclical/struggling (5y DCF)
SMA 50$2.12 (Market Anchor value)
SMA 20 / Bollinger Mid$3.79
Bollinger Width / SMA209912.4% (drives anchor stability)
Net Debt$0.0B
Market Cap$0B
Peers used for multiples: AMGN, BIIB, EXEL, GILD, KRYS, MRNA, NBIX, RVMD
Blended Fair Value
Current Price
$12.64
Deviation
MethodImplied PriceWeightDetail
DCF n/a 0%
DDM (Gordon) n/a 0%
Peer P/E n/a 0% median 22.1× · 6 peers
Peer EV/EBITDA n/a 0% median 13.9× · 6 peers
Peer P/B n/a 0% median 6.6× · 8 peers
Peer P/S n/a 0% median 5.2× · 7 peers
Market Anchor (SMA50) $2.12 0% stability 0% (BB-width)
Options Expected (B-L 30d) n/a 0%
As of 2026-06-12 · updated 2026-06-12 09:30:35.845000
Info
Industry (SIC)
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) (2836)
Exchange
XNAS
Market Cap
$0.0B

Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in developing novel, small-molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations (NMs) to enable the production of full-length proteins. The exaluren, the company's investigational drug product for the treatment of rare kidney diseases, and, through the collaboration with Almirall, S.A. (Almirall), ZKN-013 for the treatment of rare skin diseases.

Price History
Seasonality
MonthAvg ReturnYears of Data
Jan -0.73% 7
Feb -1.11% 8
Mar +10080.85% 8
Apr +10.71% 9
May +4.00% 9
Jun -1.04% 9
Jul -1.19% 8
Aug +37.32% 8
Sep -24.07% 8
Oct -1.73% 8
Nov -8.19% 8
Dec -1.96% 8
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators
SMA 20: $4.40
SMA 50: $2.39
SMA 200: $4.05
Current: $13.52
EMA 12: $7.56
EMA 26: $4.94
MACD: 2.6184 | Signal: 1.1621
BULLISH
ADX (14): 49.35
STRONG TREND
+DI: 51.37
−DI: 6.17
Momentum Oscillators
RSI (14): 79.90
OVERBOUGHT
Stoch %K: 91.81
Stoch %D: 89.22
Williams %R: -14.78
Volume & Volatility
BB Upper: $12.59
BB Lower: $-3.79
OVERBOUGHT
OBV: 7,000,936
Vol SMA 20: 27,675
Vol ROC: 662.80%
ATR: $2.25
True Range: $4.46
HV 20: 2447.0%
HV 30: 2017.7%
HV 60: 2006.8%

Data Summary
Data Points: 500
Last Updated: 2026-06-12T21:15:08.946000
Date Range: 2023-01-13T00:00:00 – 2026-06-12T00:00:00
AI Analysis

Choose Frenzy-Fast™ for quick analysis or Frenzy-Pro™ for comprehensive analysis.

Analysis includes technical indicators, news sentiment, risk assessment, and specific price levels to watch.

News
Options Activity
IV Rank (30D)
0
IV Rank (7D)
0
Avg IV
0.0%
Spread Scanner GPU

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score (GPU scanner)

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.

Stage 2 — Skew Adjustment (±25% cap)

RR25 and BF25 from the live options chain. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Enter a ticker to scan for optimal spread opportunities.

Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.

Volatility Surface

Enter a ticker to render the implied volatility surface.

IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
Beta (1Y vs SPY)
-2863.61
Correlation (SPY)
-22.1%
0.05
Ann. Volatility
179961.2%
SPY Volatility
13.9%

Negative beta - stock moves opposite to market

Beta & Alpha Over Time
Institutional Ownership (13F)

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

# Filer Shares Value % of Total % of Float Period
# Filer Notional Value % of Total Period
# Filer Notional Value % of Total Period
Insider Activity
Latest: 2026-06-10
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2026-06-10 Sumit Aggarwal President and CEO Grant (A) +328,833 opt EDGAR
2026-06-10 Stephen W Webster Director Grant (A) +13,587 opt EDGAR
2026-06-10 Nina S Kjellson Director Grant (A) +13,587 opt EDGAR
2026-06-10 Alan Edmund Walts Director Grant (A) +8,590 opt EDGAR
2026-06-10 Steven D Rubin Director Grant (A) +4,018 opt EDGAR
2026-06-05 Domicilium Real Estate Fund III LP 10%+ Owner Other (J) −113,636 EDGAR
2023-01-31 Tomer Kariv Director Grant (A) +2,859 opt EDGAR
2023-01-31 Lindsay Androski Director Grant (A) +2,859 opt EDGAR
2023-01-31 Alan Edmund Walts Director Grant (A) +2,859 opt EDGAR
2023-01-31 Steven D Rubin Director Grant (A) +2,859 opt EDGAR
2023-01-27 VIJAY MODUR HEAD OF R&D Grant (A) +30,000 opt EDGAR
2023-01-27 Sumit Aggarwal PRESIDENT AND CEO Grant (A) +68,700 opt EDGAR
2022-07-06 Lindsay Androski Director Grant (A) +40,000 opt EDGAR
2022-06-17 Jasbir Seehra Director Grant (A) +20,000 opt EDGAR
2022-06-17 Gadi Veinrib Director Grant (A) +20,000 opt EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
Insider Holdings
19 insiders · @ $13.52
Officers, directors, and 10%+ owners ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
# Insider Role Shares Disclosed Exposure Lifetime OM Net Filings Last Filed
1 RAJESH B PAREKH Director 4,827,129 $65.26M $3.33M 4 2022-06-17
2 Ran Nussbaum Director 3,679,797 $49.75M $13.21M 9 2022-06-17
3 Gilad Shabtai 10%+ Owner 3,351,770 $45.32M $731.2K 1 2018-05-01
4 Martijn Kleijwegt Director 2,953,673 $39.93M $2.92M 4 2020-05-22
5 Tomer Kariv Director 2,287,937 $30.93M $13.21M 9 2023-01-31
6 Pontifax Management 4 G.P. (2015) Ltd. 10%+ Owner 616,592 $8.34M $49.00M 2 2021-05-17
7 Silvia Noiman Chief Executive Officer 490,789 $6.64M $0 4 2020-05-22
8 Pontifax IV GP L.P. 10%+ Owner 468,585 $6.34M $17.06M 2 2020-05-22
9 Sumit Aggarwal President and CEO 279,158 $3.77M $0 5 2026-06-10
10 Robert Ward CHAIRMAN AND CEO 244,267 $3.30M $71.7K 8 2020-03-03
11 VIJAY MODUR HEAD OF R&D 154,953 $2.09M $0 4 2023-01-27
12 Pedro Huertas Chief Medical Officer 137,725 $1.86M $0 2 2018-05-18
13 Daniel E. Geffken INTERIM CFO 50,000 $676.0K $36.0K 2 2021-12-01
14 Gregory C. Williams CHIEF EXECUTIVE OFFICER 44,629 $603.4K $0 12 2021-02-26
15 Alan Edmund Walts Director 37,695 $509.6K $0 6 2026-06-10
16 Neil S. Belloff COO, GENERAL COUNSEL &CORP SEC 32,699 $442.1K $0 15 2021-07-30
17 Domicilium Real Estate Fund III LP 10%+ Owner 14,285 $193.1K $0 1 2026-06-05
18 GREGORY L WEAVER CHIEF FINANCIAL OFFICER 11,517 $155.7K $0 4 2020-03-16
19 David P. Snow CHIEF BUSINESS OFFICER 4,205 $56.9K $0 6 2020-03-04
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
ETF Holders
# ETF Provider Weight $ Exposure ETF AUM As Of
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.

P/B Ratio-1.9
EV/EBITDA-3.6
ROE62.7%
Debt/Equity-0.17